News

SCY-078 is being developed as both an oral and IV formulation to treat invasive and life-threatening fungal infections including candidemia and invasive aspergillosis. The study will assess the

Of the total amount, the company will spend €5bn for preclinical research through 2020, and €1.5bn will go to collaborations with external partners. The move is intended to

The drug can now be used in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with human immunodeficiency virus

AxioMx develops recombinant antibody technologies. The company offers a range of custom antibody discovery and development services for the research, diagnostic and therapeutic marketplaces. Abcam will pay $20m

The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors. Amplyx will use the funding to advance the

The open label trial is designed to evaluate the safety and efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone in up to 80 patients with locally

RESTASIS is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of

This novel supplement can be added to an optimized serum free media for greater protein yield or used as a culture media in place of FBS or other

The company will interpret samples in rare disease and cancer as part of the project, which is being undertaken by Genomics England. The project intends to sequence 100,000